Pyrrosia

Pyrrosia: A Comprehensive Reference

1. Identity and Botanical Classification

Pyrrosia Mirbel is a genus of ferns belonging to the family Polypodiaceae, placed within the subfamily Platycerioideae. Pyrrosia is a genus of about 100 fern species in the polypod family, Polypodiaceae. The Latin name Pyrrosia comes from the Greek pyrrhos (red), which refers to its leaves that are red due to the sporangia. An alternative description of the etymology is provided by the Hardy Fern Foundation: the common name for the genus is "felt fern," and the Greek pyrros means flame-colored, in reference to the reddish lamina (leaf surface) scales of some species.

The genus contains approximately 51–100 species and is widely distributed in Asia, ranging from Australia and New Zealand to Siberia and from Africa to various south Pacific islands. Like other species in Polypodiaceae, the species of Pyrrosia are generally epiphytic on trees or rocks, with a few species being terrestrial. Pyrrosia is well circumscribed by stellate (star-shaped) hairs and a characteristic connective venation pattern, which are two key characters to understanding the evolution of Polypodiaceae.

Medicinally, the genus is most important through three species formally recognized in the Chinese Pharmacopoeia:

• Pyrrosia lingua (Thunb.) Farwell — the Tongue Fern or Felt Fern, the most widely recognized species
• Pyrrosia petiolosa (Christ) Ching — the Stalked Tongue Fern
• Pyrrosia sheareri (Baker) Ching — the Sheare's Tongue Fern

The three official species in the Chinese Pharmacopoeia are Pyrrosia sheareri (Lushan Shi Wei), Pyrrosia lingua (Shi Wei), and Pyrrosia petiolosa (You Bing Shi Wei). Additional medicinally used but non-pharmacopoeial species include P. longifolia, P. piloselloides, P. lanceolata, P. calvata, P. gralla, P. porosa, and P. subfurfuracea.

In terms of ecology, most species of Pyrrosia are drought tolerant, and five species have been reported to use the crassulacean acid metabolism (CAM) pathway. The highest diversity of the genus is found in the eastern Himalaya and in Sumatra, with 12 species each.

1.1 Physical Description of Key Medicinal Species

Pyrrosia lingua, the most commonly recognized species, is a medium-sized evergreen fern that can reach up to 30 cm tall. It has a long, slender, creeping rhizome covered in lance-shaped brownish scales. The simple, undivided fronds are upright and leathery, lance-shaped to oval, with olive-green upper surfaces and distinctive felted cinnamon to tan undersides covered in stellate (star-shaped) hairs. When mature, the undersides bear dense, nearly elliptical clusters of sporangia that appear as reddish-brown dots. The plant grows as an epiphyte on rocks and tree trunks in low-altitude forests, at elevations of 100 to 1,800 metres.

The key distinguishing features of authentic material are: Pyrrosia sheareri has the largest leaves (10–25 cm) with an asymmetric ear-shaped base; P. lingua has medium lance-shaped leaves (8–12 cm) with a symmetric wedge base and neatly arranged spore clusters; P. petiolosa has the smallest leaves (3–8 cm) that curl into tubes when dried.

P. lingua is a more northern species, found from Korea through Indo-China and Thailand to Nepal and northern India. Pyrrosia petiolosa is the hardiest species in the genus, with Siberian forms being reliable in USDA Hardiness Zone 5.

1.2 Drug Name and Common Names

Together with P. petiolosa, P. lingua is sold as the Korean crude drug "suk wi." Leaves of Pyrrosia species constitute the Chinese medicine "shi-wei," or "Folium Pyrrosiae." Pyrrosiae Folium (called "Shiwei" in Chinese) is a commonly used Chinese herbal medicine originating from the aerial part of several Pyrrosia plants (Polypodiaceae). In the Western herbal market, Pyrrosia species are variously called felt fern, tongue fern, dragon-scale fern (for P. piloselloides), and lanceleaf tongue fern (for P. lanceolata).

1.3 Common Preparations and Dosage Forms

Pyrrosia sheareri, Pyrrosia lingua, and Pyrrosia petiolosa can be gathered in any season. People gather them, remove their rhizomes and roots, wash them with water, cut them into pieces, dry them in the sun or shade, shake out their fines, and make them into Chinese herbal medicines. The predominant medicinal part is the leaf (frond), used either fresh or in dried form. The drug enters commerce as:

• Dried whole leaves (crude drug) — for decoction preparation
• Powdered herb — as used in some animal studies (e.g., Pyrrosia lingua powder)
• Ethanol and aqueous extracts — used experimentally and in some prepared medicines
• Ethyl acetate fractions — the fraction found most active in several pharmacological studies

The species of Pyrrosia mentioned are not available commercially in large quantities but are fairly widespread in cultivation in fern collections, and spores are listed in several spore banks. Dried leaves collected for herbal medicines are traded locally.

Quality adulteration is a recognized concern. The most common quality problem with Shi Wei is species substitution. The Chinese Pharmacopoeia recognizes only three species (P. sheareri, P. lingua, and P. petiolosa), but related species are frequently found as adulterants: Beijing Shi Wei (P. davidii), Southwest Shi Wei (P. gralla), Felt Shi Wei (P. subfurfuracea), and Bare Shi Wei (Lemmaphyllum microphyllum). Although these are all Polypodiaceae ferns with similar appearance, they lack the same active compound profile and therapeutic potency.

2. Traditional and Historical Use

2.1 Chinese Traditional Medicine (TCM)

Shi Wei, commonly known as Folium Pyrrosiae, first appeared in Shennong Ben Cao Jing in the late Western Han Dynasty (around 100 BCE). This places its documented use in China at over two millennia. In China and Japan, a decoction of P. lingua has been known for thousands of years as a diuretic for treatment of various disorders of the urinary tract.

Pyrrosiae Folium has been used for a long time in Chinese medicine practice for the treatment of urinary infection, urolithiasis, hematuria, abnormal uterine bleeding, cough and asthma caused by damp heat, and phlegm in the lung.

According to the Compendium of Materia Medica, the medicinal nature of Shi Wei is slightly cold, with a sweet and bitter taste. It has a certain therapeutic effect on the pathological changes of the lung and bladder meridians.

Within TCM, a clinical distinction was drawn between the different source species: P. sheareri is traditionally called "Great Shiwei" due to its relatively larger leaves, and it is mainly used to treat trachitis in clinical practice, while those originating from P. lingua or P. petiolosa are referred to as "Little Shiwei" due to their relatively smaller leaves and are used to treat nephritis.

Pyrrosia calvata (Baker) Ching is a rare epiphytic fern on trunks or rocks; its whole plant is used in traditional Chinese medicine as Shiwei (Folium Pyrrosiae) to promote hemostasis and diuresis. P. sheareri, found in China, is used on a large scale to treat bacillary dysentery.

2.2 Korean Traditional Medicine

Together with P. petiolosa, P. lingua is sold as the Korean crude drug "suk wi." The primary use in Korean traditional medicine parallels that of TCM, centered on urinary tract disorders and as a diuretic.

2.3 Traditional Use in South and Southeast Asia

P. petiolosa is used as a traditional Oriental medicine and belongs to the "li-shui-shen-shih" (water-promoting, dampness-draining) category of drugs. It is used traditionally to treat urinary tract infections and urolithiasis.

Pyrrosia piloselloides (PP) is a type of fern that grows in South East Asia which has been used as traditional medicine by aboriginal people to cure various health problems such as cough and dysentery. The leaves of P. longifolia are utilized in certain regions of Indonesia and the Pacific Islands to make a decoction that helps relieve labor-associated pains.

Traditional preparations across these cultures commonly took the form of aqueous decoctions of dried leaves, though fresh leaf juice was also applied locally in some regions. Pyrrosia species are mainly used medicinally and some are also used as ornamentals. Most species listed have succulent leaves, the juice of which is applied locally for various purposes.

3. Key Phytochemical Constituents and Active Compounds

Multiple classes of secondary metabolites have been isolated from various Pyrrosia species. The chemical makeup varies by species, growing region, and harvest conditions, but several marker compounds are consistently reported.

3.1 Phenolic Acids and Xanthone Glycosides

Three active constituents in seven species of Folium Pyrrosiae — mangiferin, isomangiferin, and chlorogenic acid — have been determined as the primary chemical markers.

Mangiferin is a C-glucosylxanthone (chemically designated as 2-C-β-D-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone) and is regarded as one of the principal bioactive components. The chemical structure of mangiferin consists of a xanthone core with a β-D-glucopyranosyl moiety attached at the C2 position. This unique structural feature contributes to mangiferin's ability to scavenge free radicals and modulate various signaling pathways such as transcription regulators, serine/threonine kinases, cyclins, growth hormones, cytokines, and chemokines involved in the pathogenesis of numerous diseases including cancer, diabetes, neurodegeneration, and infections.

Chlorogenic acid was selected as the chemical marker for quality control by the Chinese Pharmacopoeia. Chlorogenic acid was selected as the chemical marker for quality control by the Chinese Pharmacopoeia due to its remarkable pharmacological activities, including anticancer, antioxidant, and antibacterial activities, as well as its protection of endothelial cells and metabolic modulation of glucose and fat.

3.2 Flavonoids and Flavonoid Glycosides

Shi Wei contains quercetin, isoquercitrin, trifolin, astragalin, liquiritin, mangiferin, isomangiferin, vitexin, luteolin, luteoloside, kaempferol, diosmetin, ferulic acid, rutin, daucosterol, β-sitosterol, catechin, epicatechin, dammaran, hopane, cycloartane, diploptene, chlorogenic acid, caffeic acid, amino acids, fatty acids, polysaccharides, volatile oils, and some trace elements.

A new kaempferol glycoside, kaempferol-3-O-β-D-glucopyranoside-7-O-α-L-arabinofuranoside, was isolated from the EtOH extract of Pyrrosia petiolosa together with six known flavonoids already reported from the same plant. A species-specific compound, the new flavone diglycoside 7-O-[6-O-(α-L-arabifuranosyl)-β-D-glucopyranosyl]-gossypetin, named pyrropetioside, along with 13 known compounds have been isolated from Pyrrosia petiolosa.

Flavonoids are the predominant class of compounds in Pyrrosia, encompassing flavones, flavonols, flavanols, dihydroflavones, and xanthones. From P. longifolia, six secondary phytochemical metabolites were identified including naringin, catechin, quercetin, rutin, kaempferol, and mangiferin.

3.3 Sterols, Triterpenes, and Other Compounds

P. lanceolata and P. piloselloides contain alkaloids, arbutin, amygdalin, tannin, saponin, formic acid, oxalic acid, and tartaric acid. Several other compounds have been isolated from some Chinese species of Pyrrosia, among which mangiferin, isomangiferin, sucrose, β-sitosterol, and diploptene, with concentrations varying per species.

From P. calvata, a rarely studied pharmacopoeial species, only 26 natural products had been characterized previously, indicating the complexity of its secondary metabolites, including flavonoids, triterpenoids, and phenolic acids. Novel alkaloid compounds with unique skeletons — calvatine A and B — have been discovered and identified as M3 muscarinic receptor antagonists, representing a previously undescribed structural class from this genus.

The diuretic study of P. petiolosa identified active compounds including methyl chlorogenate, 2′,3′-dihydroxy propyl pentadecanoate, and β-carotene.

3.4 Inter-Species Chemical Variation

The content of the three principal constituents (mangiferin, isomangiferin, chlorogenic acid) in Folium Pyrrosiae was determined in 7 species of Chinese Pyrrosia collected in 17 districts. The results showed that these constituents varied greatly with the plant species and also varied with the districts for the same species. This variability has significant implications for standardization and quality control of commercial preparations.

4. Mechanisms of Action

4.1 Diuretic Mechanism

Hydrochlorothiazide, a diuretic commonly used for the treatment of hypertension, is often associated with serious metabolic side effects. Pyrrosia petiolosa (Christ) Ching is a traditional Chinese medicine that possesses diuretic properties, without any obvious side effects. Research into the mechanism has found that the Na-Cl cotransporter inhibitory activity of methyl chlorogenate was greater than other isolated fractions, suggesting inhibition of the renal Na-Cl cotransporter (the same target as thiazide diuretics) as at least one mechanism of action. The 2023 study concluded that P. petiolosa possesses significant diuretic activities without any obvious toxicity, with at least two possible mechanisms of action. Further study on this herb is warranted.

4.2 Anti-inflammatory Mechanism

The anti-inflammatory action of Pyrrosia preparations is attributed largely to their mangiferin and flavonoid content. Mangiferin possesses numerous pharmacological properties including antioxidative, antiaging, antitumor, antibacterial, antiviral, immunomodulatory, antidiabetic, hepatoprotective, and analgesic effects. Research studies have reported that mangiferin has important roles in anti-inflammation through the suppression of NF-κB and the MAPK signaling pathway in RAW264.7 macrophages, and immunomodulation via regulating the Bregs level and activating the Nrf2 antioxidant pathway. In cell experiments, mangiferin significantly inhibited the release of pro-inflammatory cytokines as well as their mRNA expression, including TNF-α, IL-6, IL-18, and IL-1β.

In whole-plant extract studies, in anti-inflammatory experiments, the ethanol extract of P. petiolosa at 5.0 and 10.0 mg/kg exhibited significant anti-inflammatory activity against mouse ear swelling induced by xylene, and the maximum inhibition rate reached as high as 67%.

4.3 Antioxidant Mechanism

The unique xanthonoid structure of mangiferin enables it to combat free radicals and pro-oxidants, offering protection against various pathophysiological conditions. The ethanol extract of Pyrrosia petiolosa showed antioxidant activity as determined by free radical scavenging, superoxide radical scavenging, lipid peroxidation, and hydroxyl radical-induced DNA strand scission assays.

A 2025 study using electron paramagnetic resonance (EPR) spectroscopy found that using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical as a scavenging model, the P. lingua extract (0.6 mg/mL) was able to scavenge 95.1% of 0.5 mmol/L DPPH radicals, and the P. lingua extract (0.5 mg/mL) showed a high scavenging ability against extremely short-lived ·OH radicals, with a scavenging rate of 93.6% for ·OH radicals. These are in-vitro measurements and are not directly translatable to clinical endpoints.

4.4 Antibacterial Mechanism

An in-vitro study explored the antibacterial activity of Pyrrosia petiolosa ethyl acetate extract (PPEAE) against Staphylococcus aureus. The results revealed that PPEAE had strong inhibitory activity against S. aureus, with MIC and MBC of 7.8 and 15.6 mg/mL, respectively. The transcriptional levels of virulence genes hla and sea were reduced to 14.33 and 46.39% at the MIC compared to the control. Analysing the results showed that eugenol made a great contribution to antibacterial activity.

4.5 Anti-urolithic Mechanism

PL (Pyrrosia lingua) powder and its active extracts reduce the oxalate level in urine by regulating oxalate metabolism, thus ameliorating the damage of kidney tissues and preventing kidney stone formation. The 2022 network pharmacology study found that the effect of PL on nephrolithiasis was based on quercetin and kaempferol by mediating the toll-like receptor signaling pathway.

4.6 Enzyme Inhibition: ACE and Xanthine Oxidase

Extracts of P. lingua show a moderate inhibition of the angiotensin-converting enzyme (ACE), which plays a role in the build-up of high blood pressure. The methanolic extract has a moderate inhibiting effect on xanthine oxidase, which catalyzes the conversion of hypoxanthine via xanthine to uric acid, playing a crucial role in gout. These findings are based on in-vitro biochemical assays; clinical translation has not been established.

5. Scientific Evidence by Area of Use

5.1 Urinary Tract Conditions: Urolithiasis (Kidney Stones) and Urinary Infection

This is the area with the longest traditional history and the most published preclinical research.

Pyrrosiae Folium (PF) is a commonly used Chinese herbal medicine originating from three Pyrrosia species, used for the treatment of urinary infection and urolithiasis.

Animal/Preclinical Evidence: A 2022 study published in Phytomedicine employed network pharmacology combined with in-vivo animal verification. Pyrrosia lingua (PL) is an original plant of Pyrrosiae Folium and is a traditional Chinese medicine for nephrolithiasis treatment; dry leaves of PL contained many active molecules which possess multiple physiological activities, such as kidney protection, anti-inflammatory, and immunity enhancement. In kidney stone model rats, the kidney stone model rats were fed with different doses of PL powder and PL extract. Metabolomics technology was employed to identify the active ingredients in PL extract and the microbial metabolites in rat feces. A separate rodent study found that low-dose Pyrrosiae petiolosa treatment decreased the crystallization index in the urine of mice by approximately 50% (P < 0.05), and pathological manifestations such as renal tubular dilatation and inflammatory cell infiltration under pathological sections were also attenuated compared with the modeling group. Furthermore, animal experiments showed that Pyrrosiae petiolosa treatment improves renal function and inhibits inflammatory responses in the kidneys of rats with urolithiasis.

Evidence Strength: Entirely preclinical (rodent models and in-vitro). No published randomized controlled clinical trials in humans using Pyrrosia as a standalone intervention for kidney stones could be identified in the peer-reviewed literature. The evidence is preliminary and hypothesis-generating.

5.2 Diuresis and Fluid Management

A 2023 pharmacological study on diuretic mechanisms found that extracts obtained from different polar components of P. petiolosa were analyzed for toxicity in a Kunming mouse model. The diuretic effects of the extracts were compared to that of hydrochlorothiazide in rats. No toxicity was observed in mice administered P. petiolosa extracts. The ethyl acetate fraction showed the most significant diuretic effect.

Evidence Strength: Animal (rodent) study only. No human clinical data on diuretic efficacy and dosing for Pyrrosia specifically could be confirmed.

5.3 Respiratory Conditions: Bronchitis and Asthma

Pyrrosia petiolosa is commonly used as a traditional Chinese medicine for treatment of acute pyelonephritis, chronic bronchitis, and bronchial asthma. P. petiolosa as a typical Chinese herbal medicine has been generally utilized as a Chinese native medicine formulation for treatment of chronic bronchitis, bronchial asthma, and pneumoconiosis. The objective of one study was to evaluate the anti-inflammatory and antibacterial activities of P. petiolosa ethyl acetate extract (PPEAE) against S. aureus in mice. The study found that after treatment with PPEAE, the wet/dry (W/D) weight ratio and the number of WBC decreased dramatically, and the number of S. aureus was significantly reduced.

Evidence Strength: Animal and in-vitro evidence only. Human clinical evidence for Pyrrosia in respiratory conditions is not available in the peer-reviewed literature at this time.

5.4 Anti-infective and Antibacterial Activity

In published preclinical research, Pyrrosia petiolosa was concluded to be a potential candidate for future development of a novel antibacterial and anti-inflammatory agent. P. lingua, P. petiolosa, P. sheareri, P. heterophylla, P. gralla, P. porosa, and P. subfurfuracea have been reported to possess pharmacological properties, including antitumor, anticancer, anti-inflammatory, antiviral, antioxidant, and antibacterial properties, attributed to their compounds such as flavonoids (kaempferol, quercetin, and their glycosides), flavanone (naringenin), and xanthone (mangiferin).

From P. longifolia, previous research found that the ethyl acetate extract of the species had high radical scavenging activity (IC50 = 28.22 μg/mL) and intermediate antibacterial activity against some pathogenic bacteria.

Evidence Strength: In-vitro and animal studies. No human clinical trials for infectious disease endpoints have been published for Pyrrosia.

5.5 Antiproliferative and Potential Anticancer Activity

Research into P. piloselloides identified antiproliferative effects in cell-line studies. A 2019 study published in Asian Pacific Journal of Cancer Prevention investigated anti-proliferative effects of methanol and water extracts of Pyrrosia piloselloides on the HeLa human cervical carcinoma cell line. These effects are attributed in part to the mangiferin content; many research studies have proven that mangiferin possesses antioxidant, anti-infection, anti-cancer, anti-diabetic, cardiovascular, and neuroprotective properties and that it also increases immunity. However, mangiferin is not currently being applied to clinical use because its oral bioavailability as well as its absorption in the body are too low.

Evidence Strength: Entirely in-vitro (cell-line studies). No clinical oncology evidence exists for Pyrrosia. These findings are very preliminary.

5.6 Antioxidant Activity

Multiple in-vitro studies have documented robust free-radical scavenging activity in Pyrrosia extracts. The 2025 EPR study concluded that the developed EPR spectroscopy method provides a reference for the application of P. lingua in antioxidant and clinical disease therapies. The antioxidant activity is broadly attributed to the phenolic acid and xanthone content of the plant, particularly chlorogenic acid, mangiferin, and flavonoids.

Evidence Strength: In-vitro studies; no clinical antioxidant endpoint trials exist for Pyrrosia.

5.7 Potential Cardiovascular and Metabolic Effects

Extracts of P. lingua show a moderate inhibition of the angiotensin-converting enzyme (ACE) and a moderate inhibiting effect on xanthine oxidase, which catalyzes the conversion of hypoxanthine via xanthine to uric acid and plays a crucial role in gout. These biochemical findings suggest hypothetical relevance to hypertension management and gout/hyperuricemia prevention, but no clinical evidence in humans has been established for Pyrrosia for these indications.

5.8 Hemostasis

Within TCM, Pyrrosia has also been used to promote hemostasis and treat hematuria (blood in urine). The whole plant of P. calvata is used in traditional Chinese medicine as Shiwei to promote hemostasis and diuresis. Scientific studies specifically investigating hemostatic mechanisms in Pyrrosia have not been identified in the peer-reviewed English-language literature to the extent necessary for further characterization here.

6. Body Systems and Health Areas Associated With Pyrrosia

• Renal and Urinary System: The primary application area, encompassing kidney stones (nephrolithiasis), urinary tract infections (pyelonephritis, cystitis), hematuria, and diuresis.
• Respiratory System: Traditional and ethnopharmacological use for chronic bronchitis, bronchial asthma, pneumoconiosis, and productive cough; supported by animal anti-inflammatory data.
• Cardiovascular System: In-vitro ACE inhibition activity; in-vitro xanthine oxidase inhibition relevant to gout and hyperuricemia.
• Immune/Inflammatory System: Multi-species evidence for anti-inflammatory activity via NF-κB and MAPK pathway modulation (primarily mangiferin-mediated).
• Oxidative Stress: Broad-spectrum antioxidant activity (DPPH, hydroxyl radical, superoxide scavenging) documented in in-vitro systems.
• Gastrointestinal System: Traditional use for dysentery (P. sheareri) and hematuria; P. lingua studied in relation to gut microbiota modulation and oxalate metabolism.
• Reproductive System: Traditional use in parts of Indonesia and Pacific Islands for labor-associated pain relief (P. longifolia).

7. Dosage Forms and Dosages Reported in Studies

No standardized human clinical dosages have been established in peer-reviewed literature for Pyrrosia as a standalone supplement. The following dosages are reported only as used in the preclinical studies cited:

• Anti-inflammatory rodent experiment (P. petiolosa ethanol extract): The ethanol extract at 5.0 and 10.0 mg/kg exhibited significant anti-inflammatory activity against the mouse ear swelling induced by xylene.
• Diuretic study (P. petiolosa): Extracts from different polar components of P. petiolosa were analyzed for toxicity in a Kunming mouse model, and diuretic effects of the extracts were compared to that of hydrochlorothiazide in rats. Specific mg/kg doses were not detailed in the available abstract data.
• Antibacterial in-vitro study (P. petiolosa PPEAE): The PPEAE had a strong inhibitory activity against S. aureus, with MIC of 7.8 and MBC of 15.6 mg/mL.
• Antioxidant in-vitro study (P. lingua): The PL extract at 0.6 mg/mL was able to scavenge 95.1% of 0.5 mmol/L DPPH radicals.
• Radical scavenging (P. lingua): The PL extract (0.5 mg/mL) showed a high hydroxyl radical scavenging rate of 93.6%.

In the TCM tradition, Folium Pyrrosiae is typically administered as a water decoction, though clinically used quantities in Chinese practice are not standardized in the Western evidence-based literature to a degree that allows firm dosage statements here.

8. Safety Considerations and Known Interactions

8.1 Preclinical Toxicology

Pyrrosia petiolosa (Christ) Ching is a traditional Chinese medicine that possesses diuretic properties, without any obvious side effects. In the diuretic mechanism study, no toxicity was observed in mice administered P. petiolosa extracts.

For P. piloselloides, a phytochemical screening and toxicological evaluation study used brine shrimp lethality testing: the LC50 recorded for ethanol extract was more than 1,000 ppm, which is conventionally regarded as a low-toxicity threshold in this assay model.

Mangiferin, a key active constituent, is especially important in that it has no toxicity based on available research, though mangiferin is not being currently applied to clinical use because its oral bioavailability as well as its absorption in the body are too low.

8.2 Quality Adulteration and Misidentification Risk

One of the most concretely documented safety concerns is species substitution. The most common quality problem with Shi Wei is species substitution. The Chinese Pharmacopoeia recognizes only three species, but related species are frequently found as adulterants; although these are all Polypodiaceae ferns with similar appearance, they lack the same active compound profile and therapeutic potency. Purchasing from sources without verified species identity therefore represents a quality and efficacy risk.

8.3 Chemical Constituent-Level Variability

The content of the three principal constituents (mangiferin, isomangiferin, chlorogenic acid) varied greatly with the plant species and also varied with the districts for the same species. This variability means that any dosing inferences drawn from studies with one batch or species may not apply to another.

8.4 Absence of Human Safety and Interaction Data

Formal human pharmacokinetic studies, drug-interaction assessments, or safety studies of Pyrrosia preparations in human populations have not been identified in the published peer-reviewed literature. Given that mangiferin and chlorogenic acid — two principal constituents — are known to modulate NF-κB signaling, antioxidant pathways, enzyme activity (ACE, xanthine oxidase), and renal Na-Cl co-transport, theoretical pharmacodynamic interactions with antihypertensive agents (especially ACE inhibitors and thiazide diuretics), xanthine oxidase inhibitors (allopurinol, febuxostat), and anti-inflammatory drugs cannot be excluded, but no clinical interaction studies have been published specifically for Pyrrosia.

8.5 Pregnancy and Special Populations

No peer-reviewed data on Pyrrosia use in pregnancy, lactation, pediatric populations, or people with significant renal or hepatic impairment could be identified. The traditional use of P. longifolia in Indonesian and Pacific Island practice specifically to relieve labor-related pains represents an ethnobotanical record, not a safety endorsement.

9. Evidence Summary and State of Research

The research base for Pyrrosia (Folium Pyrrosiae / Shi Wei) as a medicinal agent is as follows:

• Traditional use: Well documented over more than 2,000 years in Chinese, Korean, and wider East and Southeast Asian medicinal traditions, primarily for urinary tract and respiratory conditions.
• Pharmacopeial recognition: Three species (P. lingua, P. petiolosa, P. sheareri) are formally listed in the current Chinese Pharmacopoeia, providing official recognition of identity and quality standards.
• Phytochemistry: Reasonably well-characterized, with mangiferin, isomangiferin, chlorogenic acid, kaempferol, quercetin, and related glycosides as principal bioactive constituents.
• Mechanisms: Multiple plausible mechanisms identified in cell and animal studies (NF-κB suppression, Na-Cl cotransporter inhibition, free-radical scavenging, ACE inhibition, xanthine oxidase inhibition, oxalate metabolism modulation).
• Clinical evidence: Substantially absent. The published evidence is overwhelmingly preclinical (in-vitro cell assays and rodent models). No peer-reviewed randomized controlled trials in humans for any indication have been identified for Pyrrosia as a standalone intervention.
• Safety: Preclinical toxicology is reassuring, but formal human safety and pharmacokinetic data are lacking.

Traditional Chinese Medicine, with a history spanning over 2,000 years in treating kidney diseases, not only offers a less invasive and cost-effective option for treating and preventing urolithiasis, but also serves as a pharmacological treasure trove for the development of anti-urolithic drugs. Pyrrosia exemplifies this category: a well-established traditional agent whose scientific investigation is still in relatively early stages and in which human clinical evidence has yet to catch up with the extensive preclinical and phytochemical literature.

References

• Wei X et al. (2017). Phylogeny, historical biogeography and characters evolution of the drought resistant fern Pyrrosia Mirbel (Polypodiaceae). Scientific Reports / PMC.
• Wikipedia: Pyrrosia (genus overview, taxonomy, species list).
• Hardy Fern Foundation: Genus Characteristics — Pyrrosia.
• Pl@ntUse / PROSEA: Pyrrosia (ethnobotany, phytochemistry, traditional use).
• Antibacterial and anti-inflammatory activities of extract and fractions from Pyrrosia petiolosa (Christ et Bar.) Ching. PubMed (2014), J Ethnopharmacol.
• Antioxidant activity of Pyrrosia petiolosa. ScienceDirect / Fitoterapia (2007).
• Potential low toxic alternative for Na-Cl cotransporter inhibition: A diuretic effect and mechanism study of Pyrrosia petiolosa. PubMed (2023).
• Chemical constituents of Pyrrosia petiolosa (pyrropetioside). PubMed (2003), Chem Pharm Bull.
• Flavonoids from Pyrrosia petiolosa (Christ) Ching. PubMed (2007), J Asian Nat Prod Res.
• [Botanical survey and quality evaluation of Chinese drug shiwei (folium Pyrrosiae)]. PubMed (1991), Zhongguo Zhong Yao Za Zhi.
• [Determination of active constituents in shi-wei (Folium Pyrrosiae) by HPLC]. PubMed (1992), Yao Xue Xue Bao.
• Comparative Evaluation of Chemical Profiles of Pyrrosiae Folium Originating from Three Pyrrosia Species by HPLC-DAD. PMC / Molecules (2017).
• Molecular mechanism of Pyrrosia lingua in the treatment of nephrolithiasis: Network pharmacology analysis and in vivo experimental verification. PubMed / Phytomedicine (2022).
• Molecular mechanism of Pyrrosia lingua in the treatment of nephrolithiasis. ScienceDirect / Phytomedicine (2022).
• Analysis of the HPLC fingerprint and QAMS from Pyrrosia species. ScienceDirect (2016).
• Antibacterial activity of Pyrrosia petiolosa ethyl acetate extract against Staphylococcus aureus by decreasing hla and sea virulence genes. PubMed (2017).
• Anti-inflammatory and antibacterial activities of Pyrrosia petiolosa ethyl acetate (PPEAE) against Staphylococcus aureus in mice. PubMed (2021).
• Phytochemicals from Pyrrosia longifolia (Burm. f.) C.V. Morton with antibacterial activity. PMC (2025).
• Antioxidant activity of herbal medicine Pyrrosia lingua evaluated by electron paramagnetic resonance spectroscopy. RSC Analytical Methods (2025).
• Calvatine A and B, pyrrolidone alkaloids as M3 receptor antagonists from Pyrrosia calvata. ScienceDirect (2025).
• Anti-Inflammation and Anti-Pyroptosis Activities of Mangiferin via Suppressing NF-κB/NLRP3/GSDMD Signaling. PMC (2022).
• Mangiferin as New Potential Anti-Cancer Agent and Mangiferin-Integrated Polymer Systems. PMC (2021).
• From Nature to Nanotechnology: The Bioactivities of Mangiferin Explored. PMC (2025).
• Phytochemical screening and toxicological evaluation of Pyrrosia piloselloides extracts. ResearchGate (2018).
• Me & Qi: Shi Wei (Pyrrosiae Folium) — TCM Herb Reference.